Pharsight

Noctiva patents expiration

NOCTIVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579321 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin
May, 2023

(4 months ago)

US7405203 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin
May, 2023

(4 months ago)

US7799761 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin
Sep, 2024

(11 months from now)

US11419914 SERENITY PHARMS LLC Safe desmopressin administration
Jun, 2030

(6 years from now)

US9539302 SERENITY PHARMS LLC Safe desmopressin administration
Jun, 2030

(6 years from now)

Noctiva is owned by Serenity Pharms Llc.

Noctiva contains Desmopressin Acetate.

Noctiva has a total of 5 drug patents out of which 2 drug patents have expired.

Expired drug patents of Noctiva are:

  • US7579321
  • US7405203

Noctiva was authorised for market use on 03 March, 2017.

Noctiva is available in spray, metered;nasal dosage forms.

Noctiva can be used as treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic effect by intranasally administering a plume of droplets comprising a dose of about 0.05-5 mcg desmopressin, a method of treating nocturia due to nocturnal polyuria in adults.

The generics of Noctiva are possible to be released after 15 June, 2030.

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 03 March, 2017

Treatment: A method of treating nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic e...

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

NOCTIVA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic